1. Introduction {#sec1-ijerph-15-02082}
===============

Patients undergoing dialysis have an extremely high prevalence of death (198 deaths/1000 patients/year) \[[@B1-ijerph-15-02082]\]. Among such patients, cardiovascular disease (CVD) is the major cause of death, accounting for approximately 40% of all-cause mortality \[[@B2-ijerph-15-02082]\]. In the United States Renal Data System database, the leading specific cause of cardiac death is arrhythmia or sudden cardiac arrest (SCA), accounting for the deaths of approximately 60% of patients, followed by coronary heart disease (CHD), accounting for the deaths of approximately 20% of patients in the dialysis population \[[@B3-ijerph-15-02082]\]. Observational studies have shown a graded association between a decreased glomerular filtration rate and the risks of death and major adverse cardiovascular events (MACEs) in community-based populations \[[@B4-ijerph-15-02082],[@B5-ijerph-15-02082]\]. Thus, morbidity and mortality due to MACEs can occur from the early stages of chronic kidney disease, even before the development of end-stage renal disease (ESRD) \[[@B5-ijerph-15-02082]\]. Although the current trend of declining mortality rates among patients with ESRD \[[@B6-ijerph-15-02082]\] can be explained by the secondary prevention of CVD \[[@B7-ijerph-15-02082]\], little evidence of benefits generated by risk factor modification has been found among a dialysis population. Lipid modification with statin treatment has no benefits in terms of CVD mortality, and antiplatelet therapy reduces the risk of myocardial infarction (MI) but not CVD mortality in the dialysis population \[[@B8-ijerph-15-02082],[@B9-ijerph-15-02082]\]. The most likely explanation for ineffective treatment is that most cardiac deaths are attributed to SCA or arrhythmias, and the responsible mechanisms are still unclear. For the treatment and prevention of SCA in patients undergoing dialysis, the use of beta blockers is recommended in patients with heart failure due to systolic dysfunction \[[@B10-ijerph-15-02082]\], and angiotensin II receptor blockers may provide protection against CVD mortality \[[@B11-ijerph-15-02082]\]. Although these evidence-based therapies may partially explain the slow, steady decline in the overall cardiac mortality and SCA rate \[[@B2-ijerph-15-02082]\], the dismal outcomes and limited treatment of CHD and SCA in patients undergoing dialysis remain a challenge for nephrologists.

Syncope, defined as the transient loss of consciousness with rapid and spontaneous recovery, has been associated with acute and chronic renal failure \[[@B12-ijerph-15-02082],[@B13-ijerph-15-02082]\]. The clinical scenario of patients undergoing dialysis experiencing syncope and collapse (SC) during or after dialysis is not uncommon. In such patients, syncope is a presenting symptom of an underlying cardiac disease (aortic stenosis and coronary artery disease (CAD)), dysrhythmia (electrolyte disturbance and QT changes), pulmonary hypertension, and intradialytic or postural hypotension \[[@B14-ijerph-15-02082],[@B15-ijerph-15-02082],[@B16-ijerph-15-02082],[@B17-ijerph-15-02082],[@B18-ijerph-15-02082]\]. However, whether clinical correlations between such medical conditions and SC can translate into CVD risk in a dialysis population remains unclear. Despite the advanced knowledge of evaluation and management of syncope in a general population \[[@B12-ijerph-15-02082]\], no large-scale study has examined whether syncope is associated with the clinical outcomes of CVD in a dialysis population \[[@B19-ijerph-15-02082]\]. This study investigated the characteristics and prognosis of SC in a specialized population.

2. Materials and Methods {#sec2-ijerph-15-02082}
========================

2.1. Data Sources {#sec2dot1-ijerph-15-02082}
-----------------

This retrospective cohort study used the Registry for Catastrophic Illness Patient Database (RCIPD), a subset of the National Health Insurance Research Database, which is under the National Health Insurance (NHI) program. Taiwan launched the single-payer compulsory NHI program in 1995, and ever since, the program has covered over 99% of the population of Taiwan (23.74 million individuals in 2015) \[[@B20-ijerph-15-02082]\]. In the NHI program, an insurant with a major disease such as ESRD can apply to the Registry for Catastrophic Illness Patients, which exempts a patient from copayments for his or her medical services. The details of the RCIPD have been described in previous studies \[[@B21-ijerph-15-02082],[@B22-ijerph-15-02082]\]. Disease definitions in the RCIPD are based on the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) diagnostic codes. The Ethics Review Board of China Medical University Hospital in Taiwan approved this study (CMUH104-REC2-115-CR2).

2.2. Study Design and Participants {#sec2dot2-ijerph-15-02082}
----------------------------------

We identified patients with incident ESRD (ICD-9-CM code 585) between 1 January 1998 and 31 December 2011, and divided them into two cohorts: an SC (ICD-9-CM code 780.2) cohort and a non-SC comparison cohort. The index date was defined as the date of SC diagnosis and the corresponding non-SC comparison patients were followed from a randomly assigned date in the same year. Patients who were younger than 18 years, had undergone renal transplantation (ICD-9-CM codes V42.0 and 996.81), or had developed acute coronary syndrome (ACS; ICD-9-CM codes 410, 411.1, and 411.8), arrhythmia or cardiac arrest (ICD-9-CM codes 427.1, 427.4, 427.5, 798.1 and 798.2), or stroke (ICD-9-CM codes 430--438) before the index date were excluded from both cohorts. We used a 1:1 propensity score (PS) matching to balance baseline characteristics between the two cohorts. Baseline characteristics including age, dialysis modality, sex, and comorbidities (namely deep vein thrombosis, pulmonary embolism, valvular heart disease, atrial fibrillation, diabetes mellitus (DM), hypertension, and hyperlipidemia), were used to determine predicted disease probability obtained through logistic regression. We further classified the patients on dialysis into hemodialysis (HD) and peritoneal dialysis (PD) groups based on the dialysis modality at day 90 after the first dialysis session.

2.3. Outcomes and Relevant Variables {#sec2dot3-ijerph-15-02082}
------------------------------------

ACS (ICD-9-CM codes 410, 411.1 and 411.8), arrhythmia or cardiac arrest (ICD-9-CM codes 427.1, 427.4, 427.5, 798.1, and 798.2), stroke (ICD-9-CM codes 430--438), and overall mortality events were defined as the primary endpoint. All patients were followed from the index date to the date when the endpoint occurred or until the end of 2011. Pre-existing comorbidities that could have affected the primary outcome, namely deep vein thrombosis (ICD-9-CM code 453.8), pulmonary embolism (ICD-9-CM code 415.1), valvular heart disease (ICD-9-CM codes 394--397, 398.9 and 424.0--424.3), atrial fibrillation (ICD-9-CM code 427.31), DM (ICD-9-CM code 250), hypertension (ICD-9-CM codes 401--405), and hyperlipidemia (ICD-9-CM code 272), were investigated. These comorbidities had been diagnosed in previous inpatient claims records or in at least three successive outpatient claim records before the index date. We included SC-related medical visits as defined by outpatient visits or hospital admissions. For each patient in the SC cohort, annual medical visits were calculated based on the number of SC-related medical visits during the entire follow-up period divided by the number of follow-up person-years.

2.4. Statistical Analysis {#sec2dot4-ijerph-15-02082}
-------------------------

The Chi-squared test was used to examine the difference between the distributions of demographic status and comorbidities in categorical variables between the SC and non-SC cohorts. The Student's *t* test was used to examine the continuous variables. The cumulative incidence of endpoints (including ACS, arrhythmia or cardiac arrest, stroke, and overall mortality) was calculated using the Kaplan--Meier method, and the log-rank test was used to examine differences between the two cohorts. Univariable and multivariable Cox proportional hazard regression models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) to evaluate the risks of endpoints. Estimations were performed as crude and adjusted for possible confounders. Considering death as a competing risk factor for other CVD outcomes, we performed a competing risk survival analysis by using the subdistribution hazard function. We further assessed the effects of the dose response of SC-related medical visits on the risks of endpoints based on the number of outpatient visits and hospitalizations for SC. A *p*-value of less than 0.05 was considered significant for all tests. All statistical analyses was performed using SAS, version 9.4 (SAS Institute, Inc., Cary, NC, USA).

3. Results {#sec3-ijerph-15-02082}
==========

3.1. Incidence and Prevalence of Syncope in the Dialysis Population {#sec3dot1-ijerph-15-02082}
-------------------------------------------------------------------

A total of 132,404 patients with incident dialysis were identified between 1998 and 2011 from the Registry for Catastrophic Illness Patients. The incidence and prevalence rates of SC among the patients undergoing dialysis increased during the follow-up period ([Supplemental Figure S1](#app1-ijerph-15-02082){ref-type="app"}). In 2011, the incidence and prevalence rates of syncope were 7.05% and 10.8%, respectively. The incidence and prevalence rates of SC were higher among patients with underlying hypertension and DM than in those without.

3.2. Patient Characteristics {#sec3dot2-ijerph-15-02082}
----------------------------

The SC cohort contained 3876 patients. The patients in the non-SC cohort were selected as controls after PS matching at a 1:1 ratio ([Table 1](#ijerph-15-02082-t001){ref-type="table"}). The two cohorts were similar in terms of demographic characteristics and comorbidities. In both cohorts, approximately 51% of the patients were elderly (≥65 years) and approximately 48% were men. In the SC cohort, the proportion of patients with ESRD who received HD (90.1%) was higher than that who received PD. The major comorbid disease in both cohorts was hypertension (88.2% vs. 88.5%), followed by hyperlipidemia (40.1% vs. 40.2%), and DM (39.9% vs. 40.8%).

3.3. Risk Factors for Primary Outcomes {#sec3dot3-ijerph-15-02082}
--------------------------------------

[Table 2](#ijerph-15-02082-t002){ref-type="table"} lists the predictors of ACS, arrhythmia or cardiac arrest, stroke, and overall mortality in the PS-matched cohorts. Among these comorbidities and demographic conditions, the presence of SC and DM were universal risk factors for ACS, arrhythmia or cardiac arrest, stroke, and overall mortality. Men had higher risks of ACS and stroke, and had higher overall mortality than did women, and the risks of ACS, arrhythmia or cardiac arrest, stroke, and overall mortality increased with age. Valvular heart disease was associated with the risk of ACS and higher overall mortality. Atrial fibrillation was associated with the risk of arrhythmia or cardiac arrest, stroke, and higher overall mortality. Hypertension was associated with the risk of ACS and stroke. The patients with hyperlipidemia had a higher risk of ACS.

3.4. Primary Outcomes and Risk Stratification {#sec3dot4-ijerph-15-02082}
---------------------------------------------

In the SC cohort, the mean follow-up periods until the occurrence of the primary endpoints, namely ACS, arrhythmia or cardiac arrest, stroke, and overall mortality, were 3.51 ± 2.90, 3.43 ± 2.93, 3.74 ± 2.97, and 3.76 ± 2.98 years, respectively. [Figure 1](#ijerph-15-02082-f001){ref-type="fig"} shows that the cumulative incidence of ACS, arrhythmia or cardiac arrest, stroke, and overall mortality was significantly higher in the SC cohort than in the non-SC cohort (log-rank test, *p* \< 0.001). In both cohorts, the incidence rate of outcome events was highest for overall mortality, followed by stroke, ACS, and arrhythmia or cardiac arrest ([Table 3](#ijerph-15-02082-t003){ref-type="table"}). Overall, the incidence rates of ACS (30.1 vs. 24.7 events/1000 people/year), arrhythmia or cardiac arrest (6.75 vs. 3.51 events/1000 people/year), stroke (51.6 vs. 35.7 events/1000 people/year), and overall mortality (127.7 vs. 77.9 deaths/1000 people/year) were higher in the SC cohort than in the non-SC cohort, with adjusted HRs (aHRs) of 1.28 (95% CI = 1.11--1.46), 2.05 (95% CI = 1.50--2.82), 1.48 (95% CI = 1.33--1.66), and 1.79 (95% CI = 1.67--1.92), respectively. The sex-specific SC cohort-to-non-SC cohort relative risks of ACS, arrhythmia or cardiac arrest, stroke, and overall mortality were considerably higher for women and men. The incidence density rates of ACS, arrhythmia or cardiac arrest, stroke, and overall mortality increased with age in both cohorts. The age-specific SC cohort-to-non-SC cohort relative risk of ACS was higher in the age group of ≤49 years. The age-specific SC cohort-to-non-SC cohort relative risk of arrhythmia or cardiac arrest was higher in the age groups of 50--64 and ≥65 years. The age-specific SC cohort-to-non-SC cohort relative risks of stroke and overall mortality were higher in all age groups. The incidence density rates of ACS, arrhythmia or cardiac arrest, stroke, and overall mortality were higher among the patients who received HD than among those who received PD in both cohorts. The dialysis modality-specific SC cohort-to-non-SC cohort relative risks of ACS, arrhythmia or cardiac arrest, stroke, and overall mortality were significantly higher among the patients who received HD than among those who received PD. The patients with comorbidities in the SC cohort had considerably higher risks of ACS, arrhythmia or cardiac arrest, stroke, and overall mortality than did those with comorbidities in the non-SC cohort. The risks of ACS, arrhythmia or cardiac arrest, and stroke did not significantly differ between the patients without comorbidities in the two cohorts. However, the SC cohort-to-non-SC cohort relative risk of mortality was higher among the patients without comorbidities in the SC cohort. The SC cohort-to-non-SC cohort relative risk of stroke was significant in all stratified patients except those without comorbidities. The risk of overall mortality in all stratifications remained higher in the SC cohort than in the non-SC cohort. Based on the competing risk analysis results, the patients with SC still had higher risks of arrhythmia or cardiac arrest and stroke, with adjusted sub-hazard ratios of 1.72 (95% CI = 1.26--2.35) and 1.29 (95% CI = 1.16--1.44), than did the patients without SC ([Supplemental Table S1](#app1-ijerph-15-02082){ref-type="app"}).

Graded based on the frequency of medical visits, the effects of SC severity on the outcome risk were shown in [Table 4](#ijerph-15-02082-t004){ref-type="table"}. The patients with SC who had more than three SC-related medical visits per year exhibited a 4.57-fold increased risk of ACS (95% CI = 3.74--5.60) compared with those without SC. Similar results were observed for arrhythmia or cardiac arrest and stroke. The risk of overall mortality increased up to 4.86 (95% CI = 4.40--5.38) among those with SC who had three or more medical visits compared with those without SC (trend test, *p* \< 0.001).

4. Discussion {#sec4-ijerph-15-02082}
=============

This is the first retrospective cohort study to report a significant association between SC and MACEs or mortality. Among the patients with SC, the mean follow-up period until the occurrence of MACEs or mortality was approximately 3.5 years, indicating an ominous disease course. The presence of SC is independently associated with an increased risk of MACEs or mortality, regardless of age, sex, dialysis modality, or comorbidities. Increased frequencies of medical visits for SC episodes multiplied the risks of CVD and mortality. Given the extremely high mortality events and prevalent underlying comorbid conditions of patients undergoing dialysis, the importance of the relationship between SC and MACEs or mortality cannot be overlooked.

Despite high mortality among the dialysis population, the clinical epidemiology of CVD (incidence and prevalence) remains unreported. Patients undergoing dialysis are characterized by a high prevalence of occult and/or silent myocardial ischemia \[[@B23-ijerph-15-02082],[@B24-ijerph-15-02082]\], which has been associated with increased risks of MI, arrhythmia, and sudden cardiac death (SCD) \[[@B25-ijerph-15-02082]\]. The atypical symptoms of CVD may delay its diagnosis and adversely affect the outcomes \[[@B26-ijerph-15-02082]\]. Current guidelines recommend assessing for CVD in all patients at the initiation of dialysis regardless of symptoms \[[@B27-ijerph-15-02082]\]. However, despite this, specific guidelines for the evaluation of CAD \[[@B28-ijerph-15-02082]\], arrhythmia, and SCA in patients undergoing dialysis remain limited because of the complex pathophysiology of these conditions.

Patients undergoing dialysis have a higher risk of stroke than does the general population \[[@B29-ijerph-15-02082]\]. Older age, male sex, diabetes, and hypertension were independent risk factors for ischemic and hemorrhagic strokes in patients undergoing dialysis \[[@B29-ijerph-15-02082]\]. Until now, the preventive effect of anticoagulants on the risk of stroke was not evident, and the prerequisite issue of stroke risk assessment from atrial fibrillation in patients undergoing dialysis has rarely been discussed \[[@B30-ijerph-15-02082],[@B31-ijerph-15-02082]\]. In our study, a high incidence of stroke was noted in the SC cohort, and SC was associated with an increased risk of stroke regardless of sex, age, dialysis modality, or comorbidities ([Table 3](#ijerph-15-02082-t003){ref-type="table"}). We identified SC as an independent predictor for incident stroke, and this provided us with helpful insights into risk assessment among the dialysis population.

Most patients with SCA have no premonitory symptoms, and if such symptoms are present, they are usually nonspecific, rendering SCA the most fatal form of CVD among patients undergoing dialysis. Interacting risk factors such as comorbid coronary artery disease, myocardial abnormalities, electrolyte abnormalities, and heart failure are complex and underlie the increased incidence of SCA among the dialysis population \[[@B32-ijerph-15-02082]\]. Although we could identify patients with a high risk of SCA, the optimal approach for preventing SCA in patients undergoing dialysis is unclear and varies with risk stratification. Implantable cardioverter defibrillator (ICD) placement was associated with a significant reduction in the risk of death in patients undergoing dialysis who had survived ventricular fibrillation or cardiac arrest and is recommended as a secondary method of preventing SCA in such patients \[[@B33-ijerph-15-02082]\]. However, the estimated one-year mortality after ICD implantation remained high (approximately 40%) \[[@B2-ijerph-15-02082]\], and ICD therapy is apparently underutilized in patients undergoing dialysis \[[@B33-ijerph-15-02082]\]. These facts illustrate the predicaments faced by the medical field related to the prevention and management of CVD among the dialysis population. Identifying early symptoms to predict high-risk patients seems the most practical method of managing CVD.

In the general population, cardiac syncope may be related to CVD morbidity and mortality \[[@B13-ijerph-15-02082],[@B34-ijerph-15-02082]\]. Most associated deaths are related to concomitant underlying comorbidities rather than syncope \[[@B35-ijerph-15-02082]\]. In our study, the patients with comorbid conditions outnumbered those without comorbidities in the SC cohort. This indicated that comorbidities are prevalent in patients with SC undergoing dialysis, and the increased CVD and mortality risks in the SC cohort may be closely related to underlying comorbidities. By contrast, reflex and orthostatic syncope accounts for most syncopal episodes (30.6%) and represents a benign disease course in the general population \[[@B34-ijerph-15-02082]\]. In our study, the presence of SC did not increase the risks of ACS, arrhythmia or cardiac arrest, and stroke in patients undergoing dialysis who had no underlying comorbidities ([Table 3](#ijerph-15-02082-t003){ref-type="table"}). This suggests that SC in such patients could be largely related to non-cardiac syncope. However, in such patients, the presence of SC increased the risk of overall mortality ([Table 3](#ijerph-15-02082-t003){ref-type="table"}). This might be explained based on consequences of syncope; for example, falling and accidents among patients undergoing dialysis \[[@B36-ijerph-15-02082],[@B37-ijerph-15-02082]\]. Nevertheless, further research is required to verify this causality.

Regarding dialysis modality and patient outcomes, PD may provide relative short-term survival benefits but comparable or reduced survival after the first few years compared with HD \[[@B38-ijerph-15-02082],[@B39-ijerph-15-02082]\]. Our study results showed that PD exhibited relative benefits in terms of MACEs and survival compared with HD during the follow-up period ([Table 3](#ijerph-15-02082-t003){ref-type="table"}). In the PD and HD patients, the presence of SC considerably increased the risk of mortality, with aHRs of 2.17 and 1.66 (95% CI = 1.65--2.86 and 1.55--1.78), respectively. In the non-SC cohort, the incident rate of mortality was considerably lower among the patients who underwent PD than among those who underwent HD (54.2 vs. 80.0/1000 people/year). However, in the SC cohort, the survival rate among patients undergoing PD approached that among those undergoing HD (111.9 vs. 129.4/1000 people/year). This result indicated that the presence of SC is an independent predictor of mortality, regardless of dialysis modality. Although selection bias and differences in terms of comorbid diseases may have occurred among patients undergoing different dialysis modalities, this did not affect our result regarding the effect of SC on survival.

Our study is the first nationwide study on syncope in patients undergoing dialysis and included a large cohort of patients with a long follow-up duration. The results validated the clinical impact of SC on adverse CVD outcomes and mortality in a dialysis population. Evaluating the patients who presented with SC enabled the early detection and management of underlying diseases. Secondary prevention of MACEs might improve outcomes. Despite their strengths, the results of this study must be viewed with consideration of the following limitations. First, the patients were retrospectively identified based on diagnostic codes, which may have led to the underestimation of the true incidence in both cohorts. Second, unpredictable confounding factors may influence the outcomes of an observational study. To overcome this limitation, we used PS matching to balance the confounding factors among the cohorts, thereby mitigating the inherent difference at baseline. However, the retrospective design established the association but not the causality between exposure and outcomes. Third, the patients with SC might have not received an immediate presumptive diagnosis in their initial medical visits. In a previous study, only approximately 50% of SC cases received a definite diagnosis \[[@B12-ijerph-15-02082]\] among the general population. Evaluating the causes of SC among the patients undergoing dialysis in this study was more difficult, and the causes may be multifactorial, including orthostatic change, hypovolemia, cardiac or pulmonary diseases, and antihypertensive medication \[[@B12-ijerph-15-02082],[@B19-ijerph-15-02082],[@B40-ijerph-15-02082]\]. Because of these inherent limitations, additional studies are warranted to examine the interaction between the cause of syncope and underlying diseases in patients undergoing dialysis.

5. Conclusions {#sec5-ijerph-15-02082}
==============

This study demonstrated that as a prodrome, SC can be an effective predictor of incident MACEs and mortality, both of which have practical implications in the timely evaluation of patients undergoing dialysis.
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###### 

Comparison of demographics and comorbidities between dialysis patients with and without syncope and collapse (SC).

  Syncope and Collapse                                  
  ------------------------- ------------- ------------- -------
  Age, years                                            0.89
   ≤49                      585 (15.1)    599 (15.5)    
   50--64                   1300 (33.5)   1301 (33.6)   
   ≥65                      1991 (51.4)   1976 (51.0)   
   Mean (SD) ^\#^           63.6 (13.2)   63.7 (13.3)   0.91
  Dialysis modality                                     0.003
   Peritoneal dialysis      310 (8.00)    384 (9.91)    
   Hemodialysis             3566 (92.0)   3492 (90.1)   
  Gender                                                0.86
   Female                   2039 (52.6)   2031 (52.4)   
   Male                     1837 (47.4)   1845 (47.6)   
  Comorbidity                                           
   Deep vein thrombosis     228 (5.88)    228 (5.88)    0.99
   Pulmonary embolism       5 (0.13)      5 (0.13)      0.99
   Valvular heart disease   534 (13.8)    542 (14.0)    0.79
   Atrial fibrillation      260 (6.71)    260 (6.71)    0.99
   Diabetes                 1581 (40.8)   1547 (39.9)   0.43
   Hypertension             3432 (88.5)   3417 (88.2)   0.60
   Hyperlipidemia           1559 (40.2)   1553 (40.1)   0.89

Chi-squared test; ^\#^: Student's *t* test.
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###### 

Hazard ratios (HRs) of outcomes in association with sex, age, and comorbidities in univariate and multivariate Cox regression models.

  Variable                              ACS                        Arrhythmia/Cardiac Arrest   Stroke                     Mortality                                                                                                   
  ------------------------------------- -------------------------- --------------------------- -------------------------- -------------------------- -------------------------- -------------------------- -------------------------- --------------------------
  Syncope and collapse                  1.21 (1.06, 1.39) \*\*     1.28 (1.11, 1.46) \*\*\*    1.93 (1.41, 2.65) \*\*\*   2.05 (1.50, 2.82) \*\*\*   1.40 (1.26, 1.56) \*\*\*   1.48 (1.33, 1.66) \*\*\*   1.65 (1.54, 1.77) \*\*\*   1.79 (1.67, 1.92) \*\*\*
  Gender (Men vs. women)                1.21 (1.05, 1.38) \*\*     1.24 (1.08, 1.42) \*\*      1.24 (0.91, 1.68)          \-                         1.23 (1.11, 1.38) \*\*\*   1.20 (1.08, 1.34) \*\*\*   1.18 (1.11, 1.27) \*\*\*   1.19 (1.11, 1.27) \*\*\*
  Age, years                            1.03 (1.02, 1.03) \*\*\*   1.02 (1.02, 1.03) \*\*\*    1.03 (1.01, 1.04) \*\*\*   1.03 (1.01, 1.04) \*\*\*   1.03 (1.03, 1.04) \*\*\*   1.03 (1.03, 1.04) \*\*\*   1.05 (1.04, 1.05) \*\*\*   1.05 (1.04, 1.05) \*\*\*
  Dialysis modality                                                                                                                                                                                                                   
   Peritoneal dialysis                  1 (Reference)              1 (Reference)               1 (Reference)              1 (Reference)              1 (Reference)              1 (Reference)              1 (Reference)              1 (Reference)
   Hemodialysis                         1.32 (1.01--1.73) \*       1.09 (0.83, 1.44)           1.43 (0.75, 2.71)          \-                         1.46 (1.16, 1.83) \*\*     1.14 (0.91, 1.44)          1.23 (1.08, 1.41) \*\*     0.86 (0.75, 0.98) \*
  Baseline comorbidities (yes vs. no)                                                                                                                                                                                                 
   Deep vein thrombosis                 1.25 (0.96, 1.63)          \-                          0.97 (0.49, 1.89)          \-                         0.78 (0.60, 1.01)          \-                         1.10 (0.95, 1.26)          \-
   Pulmonary embolism                   2.46 (0.61, 9.86)          \-                          \-                         \-                         1.43 (0.36, 5.71)          \-                         1.02 (0.38, 2.71)          \-
   Valvular heart disease               1.39 (1.16, 1.68) \*\*\*   1.30 (1.08, 1.58) \*\*      1.37 (0.90, 2.09)          \-                         1.17 (1.00, 1.37) \*       \-                         1.33 (1.21, 1.46) \*\*\*   1.15 (1.05, 1.27) \*\*
   Atrial fibrillation                  1.54 (1.18, 2.01) \*\*     1.25 (0.95, 1.64)           2.59 (1.58, 4.24) \*\*\*   2.23 (1.35, 3.67) \*\*     1.51 (1.23, 1.87) \*\*\*   1.26 (1.02, 1.56) \*       2.13 (1.89, 2.40) \*\*\*   1.65 (1.46, 1.86) \*\*\*
   Diabetes                             1.88 (1.64, 2.16) \*\*\*   1.62 (1.40, 1.87) \*\*\*    1.84 (1.35, 2.51) \*\*\*   1.76 (1.28, 2.41) \*\*\*   1.90 (1.71, 2.13) \*\*\*   1.77 (1.58, 1.99) \*\*\*   1.52 (1.42, 1.63) \*\*\*   1.51 (1.41, 1.62) \*\*\*
   Hypertension                         1.99 (1.55, 2.57) \*\*\*   1.44 (1.11, 1.87) \*\*      2.06 (1.14, 3.71) \*       1.57 (0.86, 2.87)          1.98 (1.61, 2.44) \*\*\*   1.55 (1.25, 1.91) \*\*\*   1.28 (1.15, 1.43) \*\*\*   0.98 (0.88, 1.09)
   Hyperlipidemia                       1.62 (1.42, 1.86) \*\*\*   1.38 (1.19, 1.59) \*\*\*    1.29 (0.95, 1.77)                                     1.18 (1.06, 1.32) \*\*     0.97 (0.86, 1.09)          1.00 (0.93, 1.07)          \-

Crude HR: relative hazard ratio; ACS: acute coronary syndrome; 95% CI: 95% confidence interval; ^†^ Only confounding variables that were found to be significant in the univariable model were further analyzed; \* *p* \< 0.05, \*\* *p* \< 0.01, \*\*\* *p* \< 0.001.
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###### 

Incidence and adjusted HRs of ACS, arrhythmia or cardiac arrest, stroke, and mortality based on sex, age, and comorbidities between patients undergoing dialysis with and without SC.

  Variables                     Syncope and Collapse   Compared to Control                                                              
  ----------------------------- ---------------------- --------------------- ------- ------ -------- ------- -------------------------- --------------------------
  ACS                                                                                                                                   
   All                          435                    17,613                24.7    409    13,611   30.1    1.21 (1.06, 1.39) \*\*     1.28 (1.11, 1.46) \*\*\*
   Gender                                                                                                                               
    Female                      217                    9601                  22.6    204    7450     27.4    1.20 (0.99, 1.46)          1.26 (1.04, 1.53) \*
    Male                        218                    8011                  27.2    205    6161     33.3    1.22 (1.01, 1.48) \*       1.29 (1.06, 1.56) \*
    *p*-value for interaction                                                                                                           0.97
   Age, years                                                                                                                           
    ≤49                         32                     3421                  9.36    56     2930     19.1    2.16 (1.39, 3.36) \*\*\*   2.30 (1.48, 3.57) \*\*\*
    50--64                      155                    6205                  25.0    146    5030     29.0    1.16 (0.92, 1.45)          1.23 (0.98, 1.54)
    ≥65                         248                    7987                  31.1    207    5650     36.6    1.19 (0.99, 1.43)          1.17 (0.97, 1.41)
    *p*-value for interaction                                                                                                           0.16
   Dialysis modality                                                                                                                    
    Peritoneal dialysis         26                     1413                  18.4    31     1319     23.5    1.28 (0.76, 2.16)          1.30 (0.76, 2.21)
    Hemodialysis                409                    16,200                25.3    378    12,292   30.8    1.21 (1.05, 1.39) \*\*     1.24 (1.08, 1.43) \*\*
    *p*-value for interaction                                                                                                           0.86
   Comorbidity ^§^                                                                                                                      
    No                          21                     1746                  12.0    14     1282     10.9    0.91 (0.46, 1.79)          1.02 (0.51, 2.01)
    Yes                         414                    15,867                26.1    395    12,329   32.0    1.23 (1.07, 1.41) \*\*     1.27 (1.10, 1.46) \*\*\*
    *p*-value for interaction                                                                                                           0.41
  Arrhythmia/cardiac arrest                                                                                                             
   All                          65                     18,542                3.51    98     14,527   6.75    1.93 (1.41, 2.65) \*\*\*   2.05 (1.50, 2.82) \*\*\*
   Gender                                                                                                                               
    Female                      31                     10,067                3.08    49     7900     6.20    2.01 (1.28, 3.16) \*\*     2.08 (1.32, 3.27) \*\*
    Male                        34                     8475                  4.01    49     6627     7.39    1.85 (1.19, 2.87) \*\*     2.03 (1.30, 3.16) \*\*
    *p*-value for interaction                                                                                                           0.76
   Age, years                                                                                                                           
    ≤49                         5                      3526                  1.42    5      3089     1.62    1.16 (0.33, 4.02)          1.13 (0.32, 3.92)
    50--64                      25                     6561                  3.81    38     5375     7.07    1.87 (1.13, 3.11) \*       1.99 (1.20, 3.31) \*\*
    ≥65                         35                     8456                  4.14    25     6063     9.07    2.23 (1.45, 3.42) \*\*\*   2.24 (1.46, 3.43) \*\*\*
    *p*-value for interaction                                                                                                           0.49
   Dialysis modality                                                                                                                    
    Peritoneal dialysis         4                      1457                  2.74    6      1381     4.35    1.71 (0.48, 6.14)          1.73 (0.48, 6.29)
    Hemodialysis                61                     17,085                3.57    92     13,146   7.00    1.96 (1.42, 2.71) \*\*\*   2.01 (1.45, 2.78) \*\*\*
    *p*-value for interaction                                                                                                           0.75
   Comorbidity ^§^                                                                                                                      
    No                          5                      1783                  2.80    4      1322     3.03    1.07 (0.29, 3.99)          1.16 (0.31, 4.38)
    Yes                         60                     16,760                3.58    94     13,205   7.12    2.00 (1.45, 2.77) \*\*\*   2.08 (1.50, 2.88) \*\*\*
    *p*-value for interaction                                                                                                           0.37
  Stroke                                                                                                                                
   All                          611                    17,114                35.7    686    13,304   51.6    1.40 (1.26, 1.56) \*\*\*   1.48 (1.33, 1.66) \*\*\*
   Gender                                                                                                                               
    Female                      298                    9341                  31.9    338    7294     46.3    1.42 (1.21, 1.66) \*\*\*   1.49 (1.28, 1.75) \*\*\*
    Male                        313                    7773                  40.3    348    6010     57.9    1.39 (1.19, 1.62) \*\*\*   1.46 (1.25, 1.71) \*\*\*
    *p*-value for interaction                                                                                                           0.92
   Age, years                                                                                                                           
    ≤49                         55                     3384                  16.3    71     2935     24.2    1.50 (1.05, 2.13) \*       1.56 (1.10, 2.22) \*
    50--64                      176                    6104                  28.8    226    4871     46.4    1.59 (1.30, 1.93) \*\*\*   1.70 (1.40, 2.08) \*\*\*
    ≥65                         380                    7627                  49.8    389    5498     70.8    1.36 (1.18, 1.56) \*\*\*   1.37 (1.19, 1.58) \*\*\*
    *p*-value for interaction                                                                                                           0.52
   Dialysis modality                                                                                                                    
    Peritoneal dialysis         23                     1376                  16.7    57     1279     44.6    2.44 (1.50, 3.96) \*\*\*   2.46 (1.51, 4.00) \*\*\*
    Hemodialysis                588                    15,738                37.4    629    12,025   52.3    1.36 (1.22, 1.53) \*\*\*   1.40 (1.25, 1.57) \*\*\*
    *p*-value for interaction                                                                                                           0.01
   Comorbidity ^§^                                                                                                                      
    No                          36                     1686                  21.4    25     1265     19.8    0.89 (0.54, 1.49)          0.98 (0.58, 1.64)
    Yes                         575                    15,428                37.3    661    12,039   54.9    1.43 (1.28, 1.60) \*\*\*   1.48 (1.32, 1.66) \*\*\*
    *p*-value for interaction                                                                                                           0.09
  Mortality                                                                                                                             
   All                          1447                   18,569                77.9    1859   14,555   127.7   1.65 (1.54, 1.77) \*\*\*   1.79 (1.67, 1.92) \*\*\*
   Gender                                                                                                                               
    Female                      715                    10,078                71.0    942    7910     119.1   1.70 (1.54, 1.87) \*\*\*   1.82 (1.65, 2.01) \*\*\*
    Male                        732                    8491                  86.2    917    6645     138.0   1.60 (1.46, 1.77) \*\*\*   1.78 (1.61, 1.96) \*\*\*
    *p*-value for interaction                                                                                                           0.45
   Age, years                                                                                                                           
    ≤49                         99                     3527                  28.1    160    3093     51.7    1.86 (1.45, 2.40) \*\*\*   1.93 (1.50, 2.48) \*\*\*
    50--64                      367                    6572                  55.8    543    5390     100.7   1.82 (1.60, 2.08) \*\*\*   1.90 (1.66, 2.17) \*\*\*
    ≥65                         981                    8470                  115.8   1156   6072     190.4   1.70 (1.56, 1.85) \*\*\*   1.71 (1.57, 1.86) \*\*\*
    *p*-value for interaction                                                                                                           0.19
   Dialysis modality                                                                                                                    
    Peritoneal dialysis         79                     1459                  54.2    155    1385     111.9   2.02 (1.54, 2.65) \*\*\*   2.17 (1.65, 2.86) \*\*\*
    Hemodialysis                1368                   17,110                80.0    1704   13,170   129.4   1.63 (1.52, 1.75) \*\*\*   1.66 (1.55, 1.78) \*\*\*
    *p*-value for interaction                                                                                                           0.09
   Comorbidity ^§^                                                                                                                      
    No                          101                    1783                  56.7    134    1321     101.4   1.75 (1.35, 2.26) \*\*\*   2.07 (1.59, 2.69) \*\*\*
    Yes                         1346                   16,786                80.2    1725   13,233   130.4   1.64 (1.53, 1.76) \*\*\*   1.75 (1.63, 1.88) \*\*\*
    *p*-value for interaction                                                                                                           0.48

PY: person/year; Rate ^\#^: incidence rate per 1000 people/year; Crude HR: relative hazard ratio; ^†^ Only confounding variables that were found to be significant in the multivariable model were further analyzed. ^§^: comorbidity; patients with any one of the following: diabetes, hypertension, hyperlipidemia, deep vein thrombosis, pulmonary embolism, and valvular heart disease were classified into the comorbidity group. \* *p* \< 0.05, \*\* *p* \< 0.01, \*\*\* *p* \< 0.001.
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###### 

Risks of ACS, arrhythmia or cardiac arrest, stroke, and mortality among patients with SC based on frequency of medical visits for SC in Cox proportional hazard regression.

  Frequency for Medical Visit, Per Year   Event   PY       Rate ^\#^   Crude HR (95% CI)          Adjusted HR ^†^ (95% CI)
  --------------------------------------- ------- -------- ----------- -------------------------- --------------------------
  ACS                                                                                             
  Without syncope and collapse            435     17,613   24.7        1.00                       1.00
  With syncope and collapse                                                                       
  0--1                                    218     11,461   19.0        0.78 (0.66, 0.91) \*\*     0.83 (0.71, 0.98) \*
  1--2                                    61      1049     58.2        2.41 (1.84, 3.17) \*\*\*   2.26 (1.72, 2.97) \*\*\*
  ≥3                                      130     1101     118.0       4.85 (3.97, 5.93) \*\*\*   4.57 (3.74, 5.60) \*\*\*
  *p*-value for trend                                                                             \<0.001
  Arrhythmia/cardiac arrest                                                                       
  Without syncope and collapse            65      18,542   3.51        1.00                       1.00
  With syncope and collapse                                                                       
  0--1                                    51      11,926   4.28        1.23 (1.86, 1.78)          1.35 (0.93, 1.95)
  1--2                                    16      1191     13.4        4.03 (2.32, 7.02) \*\*\*   3.83 (2.19, 6.67) \*\*\*
  ≥3                                      31      1409     22.0        6.55 (4.23, 10.1) \*\*\*   6.08 (3.92, 9.42) \*\*\*
  *p*-value for trend                                                                             
  Stroke                                                                                          
  Without syncope and collapse            611     17,114   35.7        1.00                       1.00
  With syncope and collapse                                                                       
  0--1                                    332     11,379   29.2        0.82 (0.71, 0.93) \*\*     0.88 (0.77, 1.01)
  1--2                                    112     977      114.6       2.99 (2.43, 3.66) \*\*\*   2.82 (2.30, 3.47) \*\*\*
  ≥3                                      242     948      255.3       6.47 (5.55, 7.54) \*\*\*   6.26 (5.36, 7.30) \*\*\*
  *p*-value for trend                                                                             \<0.001
  Mortality                                                                                       
  Without syncope and collapse            1447    18,569   77.9        1.00                       1.00
  With syncope and collapse                                                                       
  0--1                                    1000    11,944   83.7        1.09 (1.00, 1.18) \*       1.22 (1.13, 1.33) \*\*\*
  1--2                                    307     1193     257.4       3.48 (3.07, 3.94) \*\*\*   3.24 (2.86, 3.67) \*\*\*
  ≥3                                      552     1418     389.3       5.22 (4.72, 5.76) \*\*\*   4.86 (4.40, 5.38) \*\*\*
  *p*-value for trend                                                                             \<0.001

PY: person/year; Rate ^\#^: incidence rate per 1000 people/year; Crude HR: relative hazard ratio; ^†^ Only confounding variables that were found to be significant in the multivariable model were further analyzed; \* *p* \< 0.05, \*\* *p* \< 0.01, \*\*\* *p* \< 0.001.
